Zobrazeno 1 - 10
of 147
pro vyhledávání: '"Claus Hanusch"'
Autor:
Chiara Massa, Thomas Karn, Karsten Weber, Andreas Schneeweiss, Claus Hanusch, Jens Uwe Blohmer, Dirk‐Michael Zahm, Christian Jackisch, Marion van Mackelenbergh, Jörg Thomalla, Frederik Marmé, Jens Huober, Volkmar Müller, Christian Schem, Anja Müller, Elmar Stickeler, Katharina Biehl, Peter A. Fasching, Michael Untch, Sibylle Loibl, Carsten Denkert, Barbara Seliger
Publikováno v:
Clinical and Translational Medicine, Vol 14, Iss 4, Pp n/a-n/a (2024)
Externí odkaz:
https://doaj.org/article/f921f7466a0a4b568dfafa8ea0d35cf6
Autor:
Jens Huober, Marion van Mackelenbergh, Andreas Schneeweiss, Fenja Seither, Jens-Uwe Blohmer, Carsten Denkert, Hans Tesch, Claus Hanusch, Christoph Salat, Kerstin Rhiem, Christine Solbach, Peter A. Fasching, Christian Jackisch, Mattea Reinisch, Bianca Lederer, Keyur Mehta, Theresa Link, Valentina Nekljudova, Sibylle Loibl, Michael Untch
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-12 (2023)
Abstract This retrospective pooled analysis aims to identify factors predicting relapse despite a pathologic complete response (pCR) in patients with breast cancer (BC). 2066 patients with a pCR from five neoadjuvant GBG/AGO-B trials fulfill the incl
Externí odkaz:
https://doaj.org/article/1894262e05954747a7b2989d697dd085
Autor:
Elena Laakmann, Isabell Witzel, Peter A. Fasching, Mahdi Rezai, Christian Schem, Christine Solbach, Hans Tesch, Peter Klare, Andreas Schneeweiss, Christoph Salat, Dirk-Michael Zahm, Jens-Uwe Blohmer, Barbara Ingold-Heppner, Jens Huober, Claus Hanusch, Christian Jackisch, Mattea Reinisch, Michael Untch, Gunter von Minckwitz, Valentina Nekljudova, Volkmar Müller, Sibylle Loibl
Publikováno v:
Breast Cancer Research, Vol 21, Iss 1, Pp 1-8 (2019)
Abstract Background The incidence of central nervous system (CNS) metastases in breast cancer patients is rising and has become a major clinical challenge. Only few data are published concerning risk factors for the development of CNS metastases as a
Externí odkaz:
https://doaj.org/article/917ee11fdd924b59b741e34137515454
Autor:
Bernd Gerber, Andreas Schneeweiss, Volker Möbus, Michael Golatta, Hans Tesch, David Krug, Claus Hanusch, Carsten Denkert, Kristina Lübbe, Jörg Heil, Jens Huober, Beyhan Ataseven, Peter Klare, Markus Hahn, Michael Untch, Karin Kast, Christian Jackisch, Jörg Thomalla, Fenja Seither, Jens-Uwe Blohmer, Kerstin Rhiem, Peter A. Fasching, Valentina Nekljudova, Sibylle Loibl, Thorsten Kühn
Publikováno v:
Cancers, Vol 14, Iss 3, p 521 (2022)
Background: The conversion of initially histologically confirmed axillary lymph node-positive (pN+) to ypN0 after neoadjuvant systemic treatment (NAST) is an important prognostic factor in breast cancer (BC) patients and may influence surgical de-esc
Externí odkaz:
https://doaj.org/article/17e84cdca4604002ae0a7a1cf9a85dd2
Autor:
Peter A. Fasching, Sabine Schmatloch, Jan Hauke, Julia Rey, Christian Jackisch, Peter Klare, Theresa Link, Claus Hanusch, Jens Huober, Andrea Stefek, Sabine Seiler, Wolfgang D. Schmitt, Christoph Uleer, Gabriele Doering, Kerstin Rhiem, Andreas Schneeweiss, Carsten Denkert, Rita K. Schmutzler, Eric Hahnen, Michael Untch, Valentina Nekljudova, Jens-Uwe Blohmer, Sibylle Loibl
Publikováno v:
Cancer Research. 83:P4-06
Background: The GeparOLA study was designed to evaluate the efficacy and safety of the combination of paclitaxel (P) plus olaparib (O) as part of neoadjuvant chemotherapy (NACT) in patients with human epidermal growth factor receptor 2 (HER2)-negativ
Autor:
Jens-Uwe, Blohmer, Theresa, Link, Mattea, Reinisch, Marianne, Just, Michael, Untch, Oliver, Stötzer, Peter A, Fasching, Andreas, Schneeweiss, Pauline, Wimberger, Sabine, Seiler, Jens, Huober, Marc, Thill, Christian, Jackisch, Kerstin, Rhiem, Christine, Solbach, Claus, Hanusch, Fenja, Seither, Carsten, Denkert, Knut, Engels, Valentina, Nekljudova, Sibylle, Loibl, John, Hackmann
Publikováno v:
JAMA Oncol
IMPORTANCE: Adjuvant denosumab might improve disease-free survival in hormone receptor (HR)–positive primary breast cancer (BC). The optimal neoadjuvant nab-paclitaxel schedule in terms of efficacy and safety is unclear. OBJECTIVE: To determine whe
Autor:
Sibylle Loibl, Michael Untch, Valentina Nekljudova, Tanja Fehm, Brian Leyland-Jones, Marion van Mackelenbergh, Jens Huober, Elmar Stickeler, Claus Hanusch, Brandon M. Young, Christian Schem, Bernd Gerber, Uwe Holtrich, Volkmar Müller, Frederik Marmé, Jan Budczies, Iris Schrader, Bruno V. Sinn, Peter A. Fasching, Knut Engels, Carsten Denkert, Christine Solbach, Karsten E. Weber, Tobias Meissner, Thomas Karn
Correlation of Affymetrix microarray expression data and IHC scoring of three genes in independent TNBC dataset
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05b486e86cf44e844dd49b0cf8194558
https://doi.org/10.1158/1078-0432.22479458.v1
https://doi.org/10.1158/1078-0432.22479458.v1
Autor:
Simone Schrodi, Claus Hanusch, Anne Andrulat, Nina Szeterlak, Oliver J. Stoetzer, Martin Pölcher, Antonia Kriegmair, Moritz Hamann, Monika Kriner, Michael Braun
Publikováno v:
Breast Care (Basel)
Introduction: The aim of the present study was to analyze the performance of Oncotype DX® multigene assay (ODX®) in patients with 0–3 lymph nodes in a high-volume community hospital. Methods: Patients with non-metastatic HR+/HER2– EBC and 0–3
Autor:
Toralf Reimer, Wolfgang Janni, Hans Tesch, Kristina Lübbe, Theresa Link, Carsten Denkert, Marianne Just, Jenny Furlanetto, Frederik Marmé, Erich Solomayer, Christian Jackisch, Wolfgang D. Schmitt, Kerstin Rhiem, Mattea Reinisch, Fenja Seither, A Forberger, Peter A. Fasching, Bruno Valentin Sinn, Michael Untch, Sibylle Loibl, Claus Hanusch, Valentina Nekljudova, Christine Solbach, Jens-Uwe Blohmer, Sabine Seiler, Sabine Schmatloch, Andreas Schneeweiss, Elmar Stickeler, Pauline Wimberger, Jens Huober, Marcus Schmidt, Laura Michel, Oliver Stötzer, Eric Hahnen
Publikováno v:
The Lancet Oncology. 22:1151-1161
Summary Background The development of anti-HER2 antibody–drug conjugates opens new therapeutic options for patients with breast cancer, including patients with low expression of HER2. To characterise this new breast cancer subtype, we have compared
Autor:
Steffi Busch, Claus Hanusch, Christian M. Kurbacher, Jörg Schilling, Janine Kreiss-Sender, Elisa Flahaut, Daniela Rezek, Martin Holländer, Meinolf Karthaus
Publikováno v:
Breast Care (Basel)
Introduction: In a prospective non-interventional study involving 2,173 patients, we showed that use of the oral fixed combination of netupitant 300 mg and palonosetron 0.5 mg (NEPA) for prevention of chemotherapy (Ctx)-induced nausea and vomiting ha